Pasithea Therapeutics Corp.
KTTA
$0.58
$0.000.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -42.21% | 91.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.95% | 95.87% | |||
| Operating Income | 19.95% | -95.87% | |||
| Income Before Tax | 71.62% | -232.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 71.62% | -232.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 71.62% | -232.88% | |||
| EBIT | 19.95% | -95.87% | |||
| EBITDA | 20.48% | -102.64% | |||
| EPS Basic | 85.11% | -94.00% | |||
| Normalized Basic EPS | 74.67% | -14.12% | |||
| EPS Diluted | 85.11% | -94.00% | |||
| Normalized Diluted EPS | 74.67% | -14.12% | |||
| Average Basic Shares Outstanding | 90.58% | 71.57% | |||
| Average Diluted Shares Outstanding | 90.58% | 71.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||